Overview

Brentuximab for Newly Diagnosed Hodgkin Disease

Status:
Active, not recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

The addition of Brentuximab vedotin (Bv) to combination chemotherapy will be safe, well tolerated and effective in children, adolescents and young adults with all stages of newly diagnosed Hodgkin lymphoma (HL).

Phase:

Phase 2

Details

Lead Sponsor:

Mitchell Cairo

Treatments:

Brentuximab Vedotin
Doxorubicin
Rituximab
Vincristine